Recentin (cediranib; AstraZeneca) is a small molecule inhibitor of all three vascular endothelial growth factor receptor (VEGFR-1, -2, -3) tyrosine kinases. The VEGF family of receptors are critical for angiogenesis and their overexpression in ovarian tumors is a sign of poor prognosis. Inhibiting the VEGF pathway blocks signaling that promotes angiogenesis and thereby inhibits tumor progression.
To date, Recentin (cediranib; AstraZeneca) is the only targeted therapy developed for ovarian cancer to demonstrate that it extends overall survival (OS). This will serve to distinguish it from currently marketed drugs in the recurrent platinum-sensitive setting, which have not shown that they extend OS. If approved, Recentin could greatly increase AstraZeneca’s share of the ovarian cancer market as it targets a larger patient population than AstraZeneca’s other approved drug, Lynparza (olaparib), and it is being evaluated as both an induction and maintenance therapy.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Recentin : Ovarian cancer
LIST OF FIGURES
8 Figure 1: Recentin for ovarian cancer – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment of Recentin for ovarian cancer
10 Figure 3: Datamonitor Healthcare’s drug assessment of Recentin for ovarian cancer
LIST OF TABLES
4 Table 1: Recentin drug profile
5 Table 2: Recentin Phase III data in ovarian cancer
6 Table 3: Recentin Phase III results in ovarian cancer
7 Table 4: Overview of early phase data for Recentin in ovarian cancer
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726